Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study

Critical Care Medicine

Volumn 35, Issue 12, 2007, Pages 2693-2701

  Werdan, Karl ^a,q   Pilz, Günter ^b   Bujdoso, Oskar ^c,d   Fraunberger, Peter ^e   Neeser, Gertraud ^f   Schmieder, Roland Erich ^g   Viell, Burkhard ^o   Marget, Walter ^b   Seewald, Margret ^p   Walger, Peter ^h   Stuttmann, Ralph ⁱ   Speichermann, Norbert ^j   Peckelsen, Claus ^k   Kurowski, Volkhard ^l   Osterhues, Hans Heinrich ^m   Verner, Ljiljana ⁿ   Neumann, Roswita ^c,d   Müller Werdan, Ursula ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Medizinisches Zentrallaboratorium GesmbH ^*

^e Medizinisches Zentrallaboratorium GesmbH   (Austria)

^f KLINIKUM AUGSBURG   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h UNIVERSITY OF BONN   (Germany)

ⁱ BG KLINIKEN BERGMANNSTROST   (Germany)

^j Hospital Ludwigsburg   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^p MedQM Berlin   (Germany)

^q MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

more..

Author keywords

Acute Physiology and Chronic Health Evaluation II score; Cytokines; Immunoglobulin G treatment; SBITS study; Sepsis; Septic shock

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALLERGIC RASH; ANAPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ERYTHEMA; FEMALE; HEART ARREST; HEART FAILURE; HUMAN; INTENSIVE CARE UNIT; LUNG CONGESTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PAPULAR RASH; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SEPSIS; TEACHING HOSPITAL; THROMBOSIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 36448971653     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000295426.37471.79     Document Type: Article

References (36)

1. Carlet J: Immunological therapy in sepsis: Currently available. Intensive Care Med 2001; 27:S93-S103
2. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30:536-555
3. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
4. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
5. Andersson J, Skansen-Saphir U, Sparrelid E, et al: Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104(Suppl):1:10-20
6. Elebute EA, Stoner HB: The grading of sepsis. Br J Surg 1983; 70:29-31
7. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity-of-disease classification system. Crit Care Med 1985; 13:818-829
8. Pilz G, Fateh-Moghadam S, Viell B, et al: Supplemental immunoglobulin therapy in sepsis and septic shock - Comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo. Protocol of a multicenter, randomized, prospective, double-blind trial. Theor Surg 1993; 8:61-83
9. Lorenz W, Neugebauer E, Pilz G, et al: Discussion forum - Methodology of clinical trials in sepsis. Theor Surg 1994; 9:10-67
10. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755
11. Pilz G, Fraunberger P, Appel R, et al: Early prediction of outcome in score-identified, postcardiac patients at high risk for sepsis, using soluble tumor necrosis factor receptorp55 concentrations. Crit Care Med 1996; 24:596-600
12. Pilz G, Gurniak T, Bujdoso O, et al: A BASIC program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. Comput Biol Med 1991; 21:143-159
13. Benzer H, Haider W, Mutz N, et al: The alveolo-arterial oxygen quotient: Standard norms, clinical findings. Anaesthesist 1979; 28:533-539
14. Werdan K: Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 2001; 7:354-361
15. Pildal J, Gotzsche PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004; 39:38-46
16. Dominioni L, Dionigi R, Zanello M, et al: Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126:236-240
17. Dominioni L, Bianchi V, Imperatori A, et al: High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg 1996; 13:430-434
18. Schedel I, Dreickhausen U, Nentwig B, et al: Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 1991; 19:1104-1113
19. Werdan K, Pilz G: Letter to the editor. Crit Care Med 1992; 20:1364-1365
20. Wortel CH, Dellinger RP: Letter to the editor. Crit Care Med 1993; 21:163-165
21. Alejandria MM, Lansang MA, Dans LF, et al: Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software; Update in 2002
22. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
23. Cafiero F, Gipponi M, Bonalumi U, et al: Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: Results of a randomized, multicenter clinical trial. Surgery 1992; 11:24-31
24. Friedman G, Silva E, Vincent J-L: Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086
25. Natanson C, Esposito CJ, Banks St, et al: The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998; 26:1927-1931
26. Darenberg J, Ihendyane N, Sjölin J, et al: StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340
27. Kaul R, McGeer A, Norrby-Teglund A, et al: Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: A comparative observational study. Clin Infect Dis 1999; 28:800-807
28. Norrby-Teglund A, Ihendyane N, Kansal R, et al: Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens. Clin Infect Dis 2000; 31:1175-1182
29. Trautmann M, Held TK, Susa M, et al: Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998; 111:81-90
30. Andersson JP, Andersson UG: Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71:372-376
31. Menezes MCS, Bernard G, Sato MN, et al: In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int Arch Allergy Immunol 1997; 114:323-328
32. Witthaut R, Busch C, Fraunberger P, et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29:1696-1702
33. Cohen J: The "failure" of clinical trials in sepsis. Curr Opinion Crit Care 1999; 330:339-340
34. Petros AJ, Marshall JC, van Saene HKF: Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet 1995; 345:369-371
35. Pilz G, Werdan K: Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock. Infection 1990; 18:253-262
36. Mohr M, Englisch L, Roth A, et al: Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and Gram-negative sepsis. Intensive Care Med 1997; 23:1144-1149